Form 4: Rallybio Corp CEO Stephen Uden Acquires 453,700 Stock Options

Stephen Uden, CEO of Rallybio Corp, reports the acquisition of 453,700 stock options on February 14, 2025, according to a Form 4 filing.

Summary

• Stephen Uden, the CEO of Rallybio Corp, filed a Form 4 with the SEC.
• The filing reports a transaction that occurred on February 14, 2025.
• Uden acquired 453,700 options to purchase common stock at an exercise price of $0.76.
• The options vest in 48 equal monthly installments until fully vested on February 14, 2029.
• The options expire on February 14, 2035.
• Following the reported transaction, Uden directly owns 453,700 derivative securities.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a standard practice and suggests confidence in the company's future performance. However, it's not a major event that would drastically alter investor sentiment.

Positives

• The grant of stock options to the CEO aligns his interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the CEO.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize and retain key executives. The size and terms of the grant are typical for a CEO of a company of Rallybio's size and stage.

Comparison to Industry Standards

• Stock option grants are a common form of compensation for executives in the biotech industry.
• Comparable companies like BioNTech and Moderna also utilize stock options as part of their executive compensation packages.
• The vesting schedule of 48 months is fairly standard, aligning with industry norms for long-term incentive plans.

Stakeholder Impact

• Shareholders may view the option grant as a positive sign, aligning management's interests with theirs.
• Employees may see the grant as a sign of the company's commitment to its leadership.

Key Dates

Keywords

Form 4, Rallybio Corp, Stock Options, Stephen Uden, RLYB, CEO, Equity Incentive Plan